ArticleInternational journal of biological sciences2009
Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages.
Article in International journal of biological sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01617083 (Antibiotic Treatment Trial for the PANDAS/PANS Phenotype), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2019Trial
- Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.Respiratory research · 2017Trial
- IgE Antibody Function and Mast Cell Activation to Egg in Children Undergoing Baked and Loosely Cooked Egg Challenges.Allergy · 2026Article
- Review
- Clinical Trials Targeting Secondary Damage after Traumatic Spinal Cord Injury.International journal of molecular sciences · 2023Review
- Immunomodulatory role of azithromycin: Potential applications to radiation-induced lung injury.Frontiers in oncology · 2023Review
- Azithromycin through the Lens of the COVID-19 Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- A Review: Antimicrobial Therapy for Human Pythiosis.Antibiotics (Basel, Switzerland) · 2022Review
- Azithromycin in viral infections.Reviews in medical virology · 2021Review
- Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.Frontiers in medicine · 2021Review
- Article
- Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.International journal of antimicrobial agents · 2020Review
- Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury.Journal of neuroinflammation · 2015Article
- Azithromycin use in patients with cystic fibrosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Review
- Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study.Pharmacology research & perspectives · 2014Article
- Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.Inflammopharmacology · 2013Review
- Efficacy of azithromycin in preventing lethal graft-versus-host disease.Clinical and experimental immunology · 2013Article
- Azithromycin distinctively modulates classical activation of human monocytes in vitro.British journal of pharmacology · 2012Article
- Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.Mediators of inflammation · 2012Review
- Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.Journal of bioterrorism & biodefense · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azithromycin (AZM), a 15-member macrolide antibiotic, possesses anti-inflammatory activity. Macrophages are important in innate and acquired immunity, and produce pro-inflammatory cytokines such as interleukin (IL)-12, which are composed of subunit p40 and p35. The key function of IL-12 is the induction and maintenance of T-helper-1 responses, which is associated with the pathogenesis of chronic inflammatory diseases. We investigated the effect of azithromycin on IL-12p40 production in macrophages after lipopolysaccharide (LPS)/interferon (IFN)-gamma stimulation. RAW264.7 macrophage cell line was pre-treated with vehicle or AZM, followed by the stimulation with LPS/IFN-gamma. We measured IL-12 production by RT-PCR and ELISA. IL-12 transcriptional regulation was assessed by electrophoretic mobility shift assay and reporter assay. Phosphorylation of activator protein (AP)-1 and interferon consensus sequence binding protein (ICSBP) was assessed by immunoprecipitation using phosphotyrosine antibody, and immunoblotting using specific antibodies against JunB and ICSBP. AZM reduced the induction of IL-12p40 by LPS/IFN-gamma in a dose dependent manner. AZM inhibited the binding of AP-1, nuclear factor of activated T cells (NFAT), and ICSBP, to the DNA binding site in the IL-12p40 promoter. AZM also reduced LPS/IFN-gamma-induced IL-12p40 promoter activity. Phosphorylation of JunB and ICSBP was inhibited by azithromycin-treatment in stimulated cells. In conclusion, AZM reduced IL-12p40 transcriptional activity by inhibiting the binding of AP-1, NFAT, and ICSBP to the promoter site. This may represent an important mechanism for regulating the anti-inflammatory effects of AZM in macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.